Merck (NYSE: MRK) provided an update on the clinical program for preladenant, Merck’s investigational adenosine A2A receptor antagonist for the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE